Last reviewed · How we verify
NCT05321979
Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Phase 3 trial testing MBA-P01 in Glabellar Frown Lines in 253 participants. Completed in 30 May 2023.
30 May 2023
Quick facts
| Lead sponsor | Medytox Korea |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 253 |
| Start date | 7 February 2022 |
| Primary completion | 30 May 2023 |
| Estimated completion | 30 May 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- MBA-P01 — full drug profile →
Conditions studied
- Glabellar Frown Lines — all drugs for Glabellar Frown Lines →
Sponsor
Medytox Korea — full company profile →
Who can join
Adults 19 to 65, any sex, with Glabellar Frown Lines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Long-term safety and efficacy of MBA-P01 for the treatment of glabellar lines: results from a multicenter, repeated-dose, open-label extension study.
Han HS, Kim WS, Lee YW, Won CH, et al · · 2024 · cited 1× · PMID 39462517 · DOI 10.1080/09546634.2024.2418919 -
Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19.
Han HS, Kim WS, Lee Y, Won CH, et al · · 2025 · PMID 40278658 · DOI 10.3390/toxins17040160
Verify or expand the search:
- PubMed search for NCT05321979
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MBA-P01
Trials testing the same drug.
- NCT05059587 — Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines · Phase 3 · completed
- NCT03547141 — Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers · Phase 1 · completed
Other Medytox Korea trials
Trials by the same sponsor.
- NCT05217355 — A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines · Phase 2 · completed
- NCT05059587 — Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05321979 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medytox Korea
- Last refreshed: 16 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05321979.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing